Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 3 of 3 results for mirikizumab

  1. Mirikizumab for treating moderately to severely active ulcerative colitis (TA925)

    Evidence-based recommendations on mirikizumab (Omvoh) for treating moderately to severely active ulcerative colitis in adults.

    Technology appraisal guidance
    Published
    25 October 2023
    View recommendations

    Sections for TA925

  2. Mirikizumab for treating moderately to severely active Crohn's disease [ID6244]

    In development [GID-TA11267] Expected publication date: 13 November 2024

    Technology appraisal guidance
    In development

  3. Risankizumab for previously treated moderately to severely active ulcerative colitis in people aged 16 and over ID6209

    In development [GID-TA11184] Expected publication date: TBC

    Technology appraisal guidance
    In development